Syndax Pharmaceuticals Management
Management criteria checks 4/4
Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 4.25 years. total yearly compensation is $7.09M, comprised of 10.6% salary and 89.4% bonuses, including company stock and options. directly owns 0.55% of the company’s shares, worth $9.80M. The average tenure of the management team and the board of directors is 3.9 years and 9.8 years respectively.
Key information
Michael Metzger
Chief executive officer
US$7.1m
Total compensation
| CEO salary percentage | 10.64% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.6% |
| Management average tenure | 3.9yrs |
| Board average tenure | 9.8yrs |
Recent management updates
Recent updates
Narrative Update • May 20
SNDX: Upcoming IPF Data Readout May Unlock Underappreciated Upside Potential
Analysts have reduced the Syndax Pharmaceuticals fair value estimate from $56.00 to approximately $53.54, reflecting a combination of slightly lower price targets and updated views on growth, profitability, and appropriate P/E levels across recent research updates. Analyst Commentary Recent Street research on Syndax Pharmaceuticals shows a mix of target price increases and reductions, with the overall effect being a modest pullback in the aggregated fair value estimate.Analysis Article • May 05
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders are probably feeling a little disappointed, since its shares...
Narrative Update • Apr 29
SNDX: Upcoming Pulmonary Fibrosis Readout Will Refine Risk Profile And Long-Term Upside
The updated analyst price target for Syndax Pharmaceuticals edges up by about $1 to $39.50 as analysts factor in new Street research that balances recent target cuts with higher targets and fresh Buy initiations. Analyst Commentary Street research on Syndax Pharmaceuticals has been active, with several firms adjusting price targets and ratings in recent weeks.
Narrative Update • Apr 14
SNDX: MAXPIRe IPF Data Will Drive Future Upside Versus Execution Risks
The updated analyst price target for Syndax Pharmaceuticals now stands at $28.00. The adjustment is based on recent Street research that weighs higher targets from several firms against more cautious revisions, as analysts reassess the risk profile and potential of the Revuforj and Niktimvo franchises.Narrative Update • Mar 31
SNDX: MAXPIRe IPF Readout Will Shape Upside Beyond Core Franchise
Analysts have lifted their blended price target on Syndax Pharmaceuticals to $57, with the change largely tied to updated views on Revuforj and Niktimvo, as well as the upcoming Phase 2 MAXPIRe readout, which some see as an additional call option that is not fully reflected in the current share price. Analyst Commentary Street research on Syndax Pharmaceuticals in recent months has centered on how much value to assign to Revuforj and Niktimvo in existing refractory settings versus the potential upside from the MAXPIRe study in idiopathic pulmonary fibrosis.Seeking Alpha • Mar 18
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
Summary Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies. I reiterate a "Strong Buy" rating as SNDX approaches profitability by 2027, supported by a solid balance sheet and significant TAM expansion opportunities. Read the full article on Seeking AlphaNarrative Update • Mar 17
SNDX: MAXPIRe IPF Readout Will Drive Future Repricing Potential
Analysts have lifted their average price target on Syndax Pharmaceuticals to a range anchored around recent Street moves toward $45 to $57, citing growing conviction in the potential contribution from Revuforj, Niktimvo and upcoming Niktimvo IPF Phase 2 MAXPIRe data, which some view as a "free call option" at current share levels. Analyst Commentary Recent research on Syndax Pharmaceuticals has focused on how much value the market may be assigning to Revuforj and Niktimvo in their current and potential indications, as well as the impact of upcoming Niktimvo idiopathic pulmonary fibrosis data from the Phase 2 MAXPIRe study.Narrative Update • Mar 02
SNDX: Leukemia Drug Progress And Citi Upgrade Will Drive Future Repricing
Narrative update on Syndax Pharmaceuticals The analyst fair value estimate for Syndax Pharmaceuticals has shifted from $27.00 to $28.00, supported by recent price target increases from firms such as Citi and BofA as analysts factor in updated expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research on Syndax Pharmaceuticals has centered on adjustments to price targets and the assumptions behind them, including revenue outlook, profitability, and P/E expectations.Narrative Update • Feb 16
SNDX: Expanded Leukemia Reach And Refined Risk Profile Will Support Long-Term Upside
Analysts have nudged their price target on Syndax Pharmaceuticals higher by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as key drivers behind the change. Analyst Commentary Analysts lifting their fair value assumptions on Syndax Pharmaceuticals are generally reacting to updated views on growth, profitability, and risk, which together support the modest US$1 move in the price target.Narrative Update • Feb 02
SNDX: FDA Leukemia Progress And UBS Upgrade Will Drive Future Repricing
Narrative Update: Syndax Pharmaceuticals Analysts recently raised their price target on Syndax Pharmaceuticals shares to $38 from $35, citing updated assumptions for growth, profitability, and future P/E that have modestly adjusted their valuation outlook. Analyst Commentary Although the latest price target is now US$38, analysts are not uniformly positive and continue to highlight areas of uncertainty around how that valuation could be realized.Narrative Update • Jan 19
SNDX: FDA Decision On Leukemia Therapy Will Drive Future Repricing Potential
Analysts have lifted their fair value estimate for Syndax Pharmaceuticals to US$27.00 from US$19.00. They cite higher Street price targets following recent FDA action on Revuforj and a willingness to use a richer future P/E multiple, even with more conservative assumptions for revenue growth and profit margins.Narrative Update • Jan 04
SNDX: Expanded Leukemia Approval Will Support Stronger Long Term Upside Potential
Analysts modestly raised their blended price target for Syndax Pharmaceuticals, reflecting recent upward revisions from $35 to $38 and from $26 to $27, as they point to supportive FDA developments and view recent stock weakness as overdone. Analyst Commentary Bullish analysts highlight that recent price target increases reflect confidence in Syndax Pharmaceuticals' ability to execute on its clinical and commercial strategy, even after market volatility following regulatory updates.Narrative Update • Dec 18
SNDX: Expanded Leukemia Approval Will Drive Stronger Long Term Commercial Momentum
Analysts have nudged their average price target on Syndax Pharmaceuticals modestly higher, to about $39.31 per share from roughly $39.31, citing strengthened conviction in long term growth and profitability following supportive regulatory developments and recent target increases from multiple covering firms. Analyst Commentary Recent target increases and reiterated positive ratings underscore a growing confidence among coverage in Syndax Pharmaceuticals, particularly around its lead asset Revuforj and the companys ability to convert regulatory wins into durable revenue growth.Narrative Update • Dec 04
SNDX: Expanded Leukemia Label Will Drive Stronger Long Term Commercial Momentum
The analyst price target for Syndax Pharmaceuticals has been raised by approximately $1 to about $39 per share, as analysts cite recent target increases across the Street and reaffirmed Buy ratings, supported by continued confidence in Revuforj's commercial outlook despite label-related concerns. Analyst Commentary Bullish analysts highlight that the recent price target increases, even if modest in absolute dollars, signal growing confidence in Syndax's execution and Revuforj's commercial ramp.Analysis Article • Nov 23
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up
Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shares have had a really impressive month, gaining 29% after a shaky...Narrative Update • Nov 20
SNDX: New FDA Approval Will Drive Continued Momentum In Oncology Markets
The analyst price target for Syndax Pharmaceuticals has been revised downward by $0.54 to $38.31. Analysts factor in lower projected profit margins and slower revenue growth, despite ongoing industry optimism around the company's recent drug approvals and market positioning.Analysis Article • Nov 06
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results
It's been a pretty great week for Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders, with its shares surging...Narrative Update • Nov 05
SNDX: Recent FDA Approvals Will Expand Market Opportunity In AML Therapy
The analyst price target for Syndax Pharmaceuticals has increased from approximately $36.55 to $38.85. Analysts cite recent FDA approvals and positive strategic developments as key factors supporting the upward revision.Analysis Article • Aug 06
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking
NasdaqGS:SNDX 1 Year Share Price vs Fair Value Explore Syndax Pharmaceuticals's Fair Values from the Community and...Narrative Update • Aug 06
Revuforj And Niktimvo Will Extend Precision Oncology Reach
Despite a sharp reduction in expected revenue growth, Syndax Pharmaceuticals’ future P/E has improved considerably, supporting a higher analyst price target, now revised up from $32.67 to $34.33. What's in the News Syndax Pharmaceuticals announced the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML), reviewed under the Real-Time Oncology Review (RTOR) program.Analysis Article • Aug 05
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • May 08
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results
Shareholders in Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) had a terrible week, as shares crashed 29% to US$9.99 in...Analysis Article • Apr 26
Is Syndax Pharmaceuticals (NASDAQ:SNDX) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Narrative • Mar 24
FDA Approvals Will Expand AML And cGVHD Treatment Options
Recent FDA approvals and strategic collaborations position Syndax to significantly enhance revenue and address unmet clinical needs in oncology.Analysis Article • Feb 07
Is Syndax Pharmaceuticals (NASDAQ:SNDX) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 22
Syndax Looks Tantalizing, But Looks Can Be Deceptive
Summary Syndax Pharmaceuticals has two approved drugs, Axatilimab and Revumenib, but the stock has fallen 50% due to competitive pressures and market skepticism. Revumenib shows promise in treating KMT2A AML and mNPM1 AML, but faces stiff competition from Kura Oncology's superior efficacy data in mNPM1 AML. Axatilimab, approved for cGVHD, differentiates itself from other treatments but operates in a differentiated market with limited revenue potential. Despite a strong cash position and promising pipeline, market concerns about revenue potential and competition keep SNDX stock depressed. Read the full article on Seeking AlphaAnalysis Article • Oct 14
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 20
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Summary Syndax Pharmaceuticals, Inc.'s stock is down 25% from recent highs, presenting a potential buying opportunity for aggressive investors as the company nears key inflection points. The company recently had its first drug it has developed with Incyte approved, and a wholly owned compound should be approved at the tail end of 2024. The stock enjoys strong analyst support, but is likely to raise additional capital in 2025. An updated analysis around Syndax Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 21
Syndax: Gearing Up For Launches
Summary Syndax Pharmaceuticals has upcoming Q3 PDUFAs for revumenib and axatilimab, both awarded priority review. Syndax pegs both upcoming PDUFAs as potential blockbusters once approved, with revumenib offering a larger revenue opportunity. Syndax's value as an investment depends on FDA approvals and successful commercialization of its molecules, making it a speculative high-risk investment. Read the full article on Seeking AlphaAnalysis Article • Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 28
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Summary Syndax Pharmaceuticals has two lead molecules in line for FDA review: revumenib for the treatment of acute leukemia and axatilimab for chronic graft-versus-host disease. Syndax is a speculative buy for those willing to take a risk on the FDA approval process. The approval and launch of revumenib in 2024 and the axatilimab deal with Incyte are important milestones to watch. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$243m |
| Dec 31 2025 | US$7m | US$754k | -US$285m |
| Sep 30 2025 | n/a | n/a | -US$312m |
| Jun 30 2025 | n/a | n/a | -US$335m |
| Mar 31 2025 | n/a | n/a | -US$331m |
| Dec 31 2024 | US$8m | US$715k | -US$319m |
| Sep 30 2024 | n/a | n/a | -US$297m |
| Jun 30 2024 | n/a | n/a | -US$264m |
| Mar 31 2024 | n/a | n/a | -US$241m |
| Dec 31 2023 | US$9m | US$678k | -US$209m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$160m |
| Mar 31 2023 | n/a | n/a | -US$153m |
| Dec 31 2022 | US$4m | US$640k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | US$818k |
| Mar 31 2022 | n/a | n/a | US$15m |
| Dec 31 2021 | US$3m | US$594k | US$25m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$2m | US$577k | -US$77m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$3m | US$540k | -US$56m |
Compensation vs Market: Michael's total compensation ($USD7.09M) is about average for companies of similar size in the US market ($USD5.47M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Metzger (54 yo)
4.3yrs
Tenure
US$7,089,213
Compensation
Mr. Michael A. Metzger is an Independent Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer since Februar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | US$7.09m | 0.55% $ 9.8m | |
| CFO, Treasurer & Principal Accounting Officer | 3.9yrs | US$2.47m | 0.16% $ 2.8m | |
| Senior VP | 9.8yrs | US$2.33m | 0.15% $ 2.6m | |
| Chief Commercial Officer | 2.2yrs | US$2.13m | 0.14% $ 2.5m | |
| Head of Research & Development and Chief Medical Officer | 1yr | US$3.08m | 0.11% $ 1.9m | |
| Co-Founder & Chief Scientific Officer | 20.6yrs | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Vice President of Investor Relations & Communications | 3.9yrs | no data | no data | |
| Chief People Officer | 3yrs | no data | no data | |
| Member of Scientific Advisory Board & Chief Medical Officer | 3.4yrs | no data | no data |
3.9yrs
Average Tenure
56yo
Average Age
Experienced Management: SNDX's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$7.09m | 0.55% $ 9.8m | |
| Co-Founder | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board & Chief Medical Officer | 9.8yrs | no data | no data | |
| Independent Director | 9.2yrs | US$511.25k | 0.10% $ 1.8m | |
| Independent Director | 9.3yrs | US$503.75k | 0.10% $ 1.8m | |
| Independent Chairman | 17.4yrs | US$947.00k | 0.20% $ 3.5m | |
| Member of Scientific Advisory Board | 9.1yrs | US$23.05k | no data | |
| Member of Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.3yrs | no data | no data |
9.8yrs
Average Tenure
65yo
Average Age
Experienced Board: SNDX's board of directors are considered experienced (9.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 07:59 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syndax Pharmaceuticals, Inc. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Jason Zemansky | BofA Global Research |